Assessing outcomes in palliative chemotherapy

Bibliography

• PORZSOLT F: Goals of palliative cancer therapy: scope of the problem. Cancer Treat. Rev (1993) 19(Suppl. A):3–14.
   Google Scholar
• SLEVIN ML, STUBBS L, PLANT HJ et al.: Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. Br. Med. J. (1990) 300(6737):1458–1460.
   PubMedGoogle Scholar
• SILVESTRI G, PRITCHARD R, WELCH HG: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. Br. Med. (1998) 317(7161):771–775.
   PubMedGoogle Scholar
• COATES A, GEBSKI V, BISHOP JF et al: Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl. I Med. (1987) 317(24):1490–1495.
   PubMed Web of Science ®Google Scholar
• THATCHER N, GIRLING DJ, HOPWOOD P, SAMBROOK RJ, QIAN W, STEPHENS RJ: Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council multicenter randomized trial. Medical Research Council Lung Cancer Working Party." Clin. Oncol. (2000) 18(2):395–404.
   Google Scholar
• TANNOCK IF, BOYD NE DEBOER G et al.: A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J. Clin. Oncol. (1988) 6(9):1377–1387.
   Google Scholar
• SMITH DC, DUNN RL, STRAWDERMAN MS, PIENTA KJ: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. j. Clin. Oncol. (1998) 16(5):1835–1843.
   PubMedGoogle Scholar
• KELLY WK, SCHER HI, MAZUMDAR M, VLAMIS V, SCHWARTZ M, FOSSA SD: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer." Clin. Oncol. (1993) 11(4):607–615.
   Google Scholar
• TANNOCK IF, OSOBA D, STOCKLER MR et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. j. Clin. Oncol. (1996)14(6):1756–1764.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF: Treating the patient, not just the cancer. N Engl. I Med. (1987) 317(24):1534–1535.
   PubMedGoogle Scholar
• BATEL-COPEL LM, KORNBLITH AB, BATEL PC, HOLLAND JC: Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. Eur: J. Cancer (1997) 33(1):29–32.
   PubMedGoogle Scholar
• FAYERS PM, HAND DJ: Generalisation from Phase III clinical trials: survival, quality of life and health economics. Lancet (1997) 350(9083):1025–1027.
   PubMedGoogle Scholar
• GEHAN EA, TEFFT MC: Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumours)? Nati Cancer Inst. (2000) 92(3):179–181.
   Google Scholar
• OSOBA D: Self-rating symptom checklists: a simple method for recording and evaluating symptom control in oncology. Cancer Treat. Rev (1993) 19(Suppl. A):43–51.
   Google Scholar
• AHLES TA, RUCKDESCHEL JC, BLANCHARD EB: Cancer-related pain - II. Assessment with visual analogue scales. j. Psychosom. Res. (1984) 28(2):121–124.
   Google Scholar
• BUCCHERI G, FERRIGNO D, TAMBURINI M. KARNOFSKY & ECOG: Performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Ear: Cancer (1996) 32A(7):1135–1141.
   Google Scholar
• YATES JW, CHALMER B, MCKEGNEY FP: Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer (1980) 45(8):2220–2224.
   PubMed Web of Science ®Google Scholar
• SCHAG CC, HEINRICH RL, GANZ PA: Karnofsky performance status revisited: reliability, validity and guidelines.j Clin. Oncol. (1984) 2(3):187–193.
   Google Scholar
• ANDO M, ANDO Y, HASEGAWA Y et al.: Prognostic value of performance status assessed by patients themselves, nurses and oncologists in advanced non-small cell lung cancer. Br.j Cancer (2001) 85(11):1634–1639.
   PubMedGoogle Scholar
• SORENSEN JB, KLEE M, PALSHOF T, HANSEN HH: Performance status assessment in cancer patients. An inter-observer variability study. Br. j Cancer (1993) 67(4):773–775.
   PubMed Web of Science ®Google Scholar
• GRIECO A, LONG CJ: Investigation of the Karnofsky Performance Status as a measure of quality of life. Health Psycho]. (1984) 3(2):129–142.
   PubMedGoogle Scholar
• SCHAAFSMA J, OSOBA D: The Karnofsky Performance Status Scale reexamined: a cross-validation with the EORTC-C30. Qualih, of Life Research (1994) 3(6):413–424.
   PubMed Web of Science ®Google Scholar
• FAYERS P, BOTTOMLEY A: Quality of life research within the EORTC - the EORTC QLQ-C30. Eur. Cancer (2002) 38 (Suppl. 4):125–133.
   Google Scholar
• CELLA DF, TULSKY DS, GREY G et al.: The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. j Clin. Oncol. (1993) 11(3):570–579.
   PubMed Web of Science ®Google Scholar
• AARONSON NK, AHMEDZAI S, BERGMAN B et al.: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. j. Natl. Cancer Inst. (1993) 85(5):365–376.
   PubMed Web of Science ®Google Scholar
• KUENSTNER S, LANGELOTZ C, BUDACH V, POSSINGER K, KRAUSE B, SEZER O: The comparability of quality of life scores, a multitrait multimethod analysis of the EORTC QLQ-C30, SF-36 and FLIC questionnaires. Ear: j Cancer (2002) 38(3):339–348.
   PubMedGoogle Scholar
• KEMMLER G, HOLZNERB, KOPP Met al.: Comparison of two quality of life instruments for cancer patients: the functional assessment of cancer therapy - general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. Clin. Oncol. (1999) 17(9):2932–2940.
   Google Scholar
• SLOAN JA, LOPRINZI CL, KUROSS SA et al: Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer." Clin. Oncol. (1998) 16(11):3662–3673.
   Google Scholar
• HOLZNER B, KEMMLER G, SPERNER-UNTERWEGER B et al.: Quality of life measurement in oncology - a matter of the assessment instrument? Ear: Cancer (2001) 37(18):2349–2356.
   PubMed Web of Science ®Google Scholar
• STOUT R, BARBER P, BURT P et al.: Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) versus external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiotherapy Oncol. (2000) 56(3)323–327.
   Google Scholar
• WALDRON D, O'BOYLE CA, KEARNEY M, MORIARTY M, CARNEY D: Quality of life measurement in advanced cancer: assessing the individual. Clin. Oncol. (1999) 17(11):3603–3611. 698
   Google Scholar
• VELIKOVA G, WRIGHT EP, SMITH AB et al: Automated collection of quality of life data: a comparison of paper and computer touch-screen questionnaires. j Clin. Oncol. (1999) 17(3):998–1007.
   PubMed Web of Science ®Google Scholar
• O'BRIEN P, CELIA D, CHANG C et al.:Feasibility of computer-assisted, immediate quality of life (QOL) monitoring in lung cancer. ASCO Proc. (2001). Abstract 982.
   Google Scholar
• SNEEUW KC, AARONSON NK, SPRANGERS MA, DETMAR SB, WEVER LD, SCHORNAGEL JH: Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses. Br. j Cancer (1999) 81(1):87–94.
   PubMedGoogle Scholar
• SLEVIN ML, PLANT H, LYNCH D, DRINKWATERJ, GREGORY WM: Who should measure quality of life, the doctor or the patient? Br. Cancer (1988) 57(1):109–112.
   Google Scholar
• OSOBA D, RODRIGUES G, MYLES J, ZEE B, PATER J: Interpreting the significance of changes in health-related quality of life scores. Clin. Oncol. (1998) 16(1):139–144.
   Google Scholar
• FAYERS PM: Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30. Eur. Cancer (2001) 37(11):1331–1334.
   PubMedGoogle Scholar
• GELBER RD, GOLDHIRSCH A, COLE BF: Evaluation of effectiveness: Q-TWiST. The International Breast Cancer Study Group. Cancer Treat. Rev (1993) 19 (Suppl. A):73–84.
   Google Scholar
• COLE BE GELBER RD, KIRKWOOD JM, GOLDHIRSCH A, BARYLAK E, BORDEN E: Quality of life-adjusted survival analysis of interferon alfa-26 adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. I. Clin. Oncol. (1996) 14(10):2666–2673.
   PubMedGoogle Scholar
• LEE CW, CHI KN: The standard of reporting of health-related quality of life in clinical cancer trials. Clin. Epidemiol. (2000) 53(5):451–458.
   Google Scholar
• SIMMONDS PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br. Med. j (2000) 321(7260):531–535.
   Google Scholar
• FIGG WD, AMMERMAN K, PATRONAS N et al: Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Investigation (1996) 14(6):513–517.
   PubMed Web of Science ®Google Scholar
• SMITH PH, BONO A, CALAIS DA SILVA F et al.: Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group. Cancer (1990) 66(5 Suppl.):1009–1016.
   Google Scholar
• MORRIS MJ, AKHURST T, KELLY K et al.: PET as an Outcome Measure for Castrate Metastatic Prostate Cancer (PC) Treated with Chemotherapy. ASCO Proc. (2001). Abstract 721.
   Google Scholar
• ELDER JS, GIBBONS RP: Ongoing Phase II & III studies of the USA National Prostatic Cancer Project. Frog. Clin. Biol. Res. (1985) 185A:427–434.
   PubMedGoogle Scholar
• NICOLSON M, WEBB A, CUNNINGHAM D et al.: Cisplatin and protracted venous infusion 5-fluorouracil (CF)-good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann. Oncol. (1995) 6(8):801–804.
   PubMedGoogle Scholar
• GLIMELIUS B, HOFFMAN K, SJODEN PO et al.: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann. Oncol. (1996) 7(6):593–600.
   PubMed Web of Science ®Google Scholar
• BURRIS HA 3RD, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Clin. Oncol. (1997) 15(6):2403–2413.
   Google Scholar
• GELBER RD: Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective. Ann. Oncol. (1996) 7(4):335–337.
   PubMedGoogle Scholar
• CARNEY DN: Lung cancer - time to move on from chemotherapy. N Engl. I Med. (2002) 346(2):126–128.
   PubMedGoogle Scholar
• CARBONE DP, MINNA JD: Chemotherapy for non-small cell lung cancer. Br. Med. J. (1995) 311(7010):889–890.
   PubMedGoogle Scholar
• CULLEN MH, BILLINGHAM LJ, WOODROFFE CM et al.: Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. j Clin. Oncol. (1999) 17(10):3188–3194.
   PubMed Web of Science ®Google Scholar
• THONGPRASERT S, SANGUANMITRA P, JUTHAPAN W, CLINCH J: Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer (1999) 24(1):17–24.
   PubMedGoogle Scholar
• HELSING M, BERGMAN B, THANING L, HERO U: Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multi-centre randomised Phase III trial. Joint Lung Cancer Study Group. Ear: J. Cancer (1998) 34(7):1036–1044.
   Google Scholar
• SMITH IE, O'BRIEN ME, TALBOT DC et al.: Duration of chemotherapy in advanced nonsmall-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. Clin. Oncol. (2001) 19(5):1336–1343.
   Google Scholar
• WOODS RL, WILLIAMS CJ, LEVI J et al.: A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br. J. Cancer (1990) 61(4):608–611.
   PubMedGoogle Scholar
• Effects of vinorelbine on quality of life and survival of elderly patients with advanced nonsmall-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. Nati Cancer Inst. (1999) 91(1):66–72.
   PubMedGoogle Scholar
• ANDERSON H, HOPWOOD P, STEPHENS RI et al.: Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small cell lung cancer-a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group Non-Small Cell Lung Cancer. Br.j Cancer (2000) 83(4):447–453.
   Google Scholar
• SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. Clin. Oncol. (2000) 18(10):2095–2103.
   Google Scholar
• ASSELT ADIV, ENCKEVORT PJV, TEN VERGERT EM et al.: Cost-effectiveness of high dose chemotherapy in patients with breast cancer. ASCO Proc. (2001). Abstract 2610.
   Google Scholar
• NEYMARK N: Assessing the quality of economic evaluations of healthcare interventions. Ann. Oncol. (2000) 11 (12):1 513-1515.
   Google Scholar
• LAPPAS JD, HAINS WORTH TR, EINARSON JJ, DOYLE SR, ARIKIAN N: PTSA Health economic evaluation of Taxol° (Paclitaxel) and carboplatin versus vinorelbine and cisplatin combination chemotherapy in the treatment of non-small cell lung cancer: a meta-analysis. ASCO Proc. (1998) Abstract 1897.
   Google Scholar
• RAMSEY SD, MOINPOUR CM, LOVATO LC, GREVSTAD PK, KELLY K, PRESANT C: An economic analysis of southwest oncology group trial s9509: cisplatin/vinorelbine versus carboplatin/ paclitaxel for advanced non-small cell lung cancer. ASCO Proc. (2000). Abstract 1913.
   Google Scholar
• LEIGHL NB, SHEPHERD FA, KWONG R, BURKES RL, FELD R, GOODWIN PJ: Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.i. Clin. Oncol. (2002) 20(5):1344–1352.
   Google Scholar
• LI N, VAN AGTHOVEN M, WILLEMSE P, UYL-DE GROOT C: A cost-utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer. Anti-Cancer Drugs (2001) 12(6):533–540.
   PubMed Web of Science ®Google Scholar